ABSTRACT
BACKGROUND: High asymmetrical dimethylarginine (ADMA) levels have been associated with endothelial dysfunction and contribute to the development of several diseases. However, data on the relationship between hepatitis B virus (HBV) and ADMA are limited. The aim of our study was to explore the relationship between ADMA and HBV by comparing the ADMA levels in patients with chronic active hepatitis B (CHB), inactive HBV carriers (carriers), and healthy volunteers (controls). METHODS: The participants were divided into three groups: 90 patients with CHB, 90 HBV carriers, and 90 controls. Serum ADMA levels were quantified using an ELISA kit (Cusabio, Wuhan, China). The data were analyzed using an ANOVA or the Kruskal-Wallis test as appropriate, with P<0.05 considered significant. RESULTS: Serum ADMA levels were significantly higher in patients with CHB (228.35±91.10 ng/mL) than in HBV carriers (207.80±75.80 ng/mL) and controls (207.61±89.10 ng/mL) (P=0.049). The clinical scores of the patients were positively correlated with ADMA levels. CONCLUSIONS: The elevated serum ADMA levels in patients with CHB confirm that HBV plays a role in vasculitis. Further investigation of the mechanisms contributing to the high levels of ADMA in CHB may contribute toward development of new treatment modalities.
Subject(s)
Humans , Enzyme-Linked Immunosorbent Assay , Healthy Volunteers , Hepatitis B virus , Hepatitis B , Hepatitis , Hepatitis, Chronic , VasculitisABSTRACT
Objective@#To compare the clinical value of FibroScan, FIB-4, APRI and AAR diagnosing hepatic fibrosis in chronic hepatitis B virus (HBV) carriers. @*Methods@#A total of 213 patients with chronic HBV carriers diagnosed by clinical and liver biopsy were selected. And according to HBeAg status, 149 patients were divided into HBeAg-positive group and 64 patients were divided into HBeAg-negative group. The liver stiffness measurements (LSM) was measured by FibroScan (FS), FIB-4, APRI and AAR values were calculated using FIB-4, APRI and AAR formula. And all patients underwent liver biopsy in the same period. According to the degree of hepatic fibrosis in Knodell, one decision point was set: significant hepatic fibrosis (S ≥ 2). The Spearman correlation analysis method was used to analyze the correlation of indicators and the area under receiver operator characteristic curves (AUROCs) of LSM, FIB-4, APRI and AAR were drawn according to liver biopsy pathology results as gold standard. The value of LSM, FIB-4, APRI and AAR diagnosing hepatic fibrosis in chronic HBV carriers was retrospectively analyzed. Retrospective analysis of FS, FIB-4, APRI and AAR were divided into 149 HBeAg-positive chronic HBV carriers (HBeAg-positive group) and 64 HBeAg-negative chronic HBV carriers (HBeAg) in 213 patients with chronic HBV carriers and HBeAg Negative group) in the diagnosis of liver fibrosis. @*Results@#The LSM of 213 patients with chronic HBV carriers, 149 patients with HBeAg-positive chronic HBV carriers and 64 patients with HBeAg-negative chronic HBV carriers were significantly correlated with liver fibrosis grade≥ 2 (P < 0.001). Regardless of HBeAg status, only LSM in the three groups had moderate evaluation efficacy for evaluating significant fibrosis(S≥2), and the positive predictive value was more than 94%, but the diagnostic accuracy was not high, the minimum was 46.31% (HBeAg-positive group), the maximum value of 67.19% (HBeAg-negative group), while the remaining three kinds of serum noninvasive liver fibrosis diagnostic model indicators and diagnostic efficacy are low. The LSM in the three groups showed a significant positive correlation with liver fibrosis grade (S)≥2. @*Conclusion@#LSM is more accurate than FIB-4, APRI and AAR in diagnosing chronic HBV carriers. Dynamically monitoring changes of LSM can earlier understand the progress of liver fibrosis than the three kinds of serology noninvasive diagnostic model and is contributed to the choice of liver biopsy timing.
ABSTRACT
Objective@#To investigate the clinical value of diagnosing hepatic fibrosis in the HBeAg negative chronic hepatitis B virus (HBV) carriers by hepatic fibrosis model of Mohamadnejad (M model) and the hepatic instantaneous elastic detector (FibroScan, FS).@*Methods@#A total of 217 patients were included: they were diagnosed as the HBeAg negative chronic HBV carriers. The value of the hepatic fibrosis was calculated by M model formula, liver stiffness measurements (LSM) was surveyed by FS, and all patients underwent liver biopsy in the same period. According to the degree of hepatic fibrosis in Knodell, one decision point was set: significant hepatic fibrosis (S ≥ 2). The Spearman correlation analysis method was used to analyze the correlation of indicators and the area under receiver operator characteristic curve (AUROC) of M model and FS was drawn.@*Results@#LSM and M model were positively correlated with the fibrosis stage of liver biopsy (r=0.64, 0.80, P=0.000, 0.000, <0.01). The diagnostic sensitivity, positive likelihood ratio, specificity and negative predictive value of M model and FS for the HBeAg negative chronic HBV carriers with significant hepatic fibrosis were 88.10%, 13.02, 93.23%, 92.50% and 82.14%, 5.20, 84.21%, 88.20%, respectively. The diagnostic AUROC of significant hepatic fibrosis were 0.927 and 0.858, respectively. It had significant statistical difference (Z=2.12, P<0.05).@*Conclusions@#M model and FS are noninvasive and ideal tools for screening HBeAg negative chronic HBV carriers with significant hepatic fibrosis. The value of diagnosing significant hepatic fibrosis in the HBeAg negative chronic HBV carriers by M model was remarkably higher than that of FS.
ABSTRACT
Objective To study the effects of tonifying kidney therapy on pathology in chronic hepatitis B virus carriers.MethodsWith the multi-center, randomized, double-blinded and placebo-controlled methods, 600 cases of chronic hepatitis B virus carriers were divided intoBushen Qingtou group,Bushen Jianpi group and control group, 200 cases in each group, and were treated withBushen Qingtou prescription,Bushen Jianpi prescription and placebo prescription respectively for 52 weeks. The pathological changes of the liver biopsy were observed by liver biopsy examination before and after treatment. Inflammatory active degree and fibrosis were scored with Knodell HAI and Ishak.Results The number of decreasing more than 2 points on Knodell HAI inBushen Qingtou group,Bushen Jianpi group and control group was 21, 18, and 6 respectively (P0.05). The number of decreasing more than 1 points on Ishak in Bushen Qingtou group,Bushen Jianpi group, and control group was 13, 12, and 9 respectively (P>0.05); the number of increasing more than 1 points on Ishak inBushen Qingtou group,Bushen Jianpi group and control group was 8, 3, and 11 respectively, with statistical significance betweenBushen Jianpi group and controlled group (P0.05), which meantBushenJianpi prescription could prevent the deterioration of liver tissue fibrosis more significantly than placebo prescription did. ConclusionTonifying kidney therapy, includingBushen Qingtou prescription andBushen Jianpi prescription, can inhibit the inflammatory activity and slow down the fibrosis progression of the chronic HBV carriers.
ABSTRACT
OBJECTIVES@#To build GPC3 gene short hairpin interference RNA (shRNA) slow virus vector, observe expression of Huh-7 GPC3 gene in human liver cell line proliferation apoptosis and the effect of GPC3 gene influencing on liver cancer cell growth, and provide theoretical basis for gene therapy of liver cancer.@*METHODS@#Hepatocellular carcinoma cell line Huh-7 was transfected by a RNA interference technique. GPC3 gene expression in a variety of liver cancer cell lines was detected by fluorescence quantitative PCR. Targeted GPC3 gene sequences of small interfering RNA (siRNA) PGC-shRNA-GPC3 were restructured. Stable expression cell lines of siRNA were screened and established with the help of liposomes (lipofectamine(TM2000)) as carrier transfection of human liver cell lines. In order to validate siRNA interference efficiency, GPC3 siRNA mRNA expression was detected after transfection by using RT-PCR and Western blot. The absorbance value of the cells of blank group, untransfection group and transfection group, the cell cycle and cell apoptosis were calculated, and effects of GPC3 gene on Huh-7 cell proliferation and apoptosis were observed.@*RESULTS@#In the liver cancer cell lines Huh-7, GPC3 gene showed high expression. PGC-shRNA-GPC3 recombinant plasmid was constructed successfully via sequencing validation. Stable recombinant plasmid transfected into liver cancer cell lines Huh-7 can obviously inhibit GPC3 mRNA expression level.@*CONCLUSIONS@#The targeted GPC3 siRNA can effectively inhibit the expression of GPC3.
ABSTRACT
Objective To explore the possibility of breast feeding in chronic asymptomatic hepatitis B virus (HBV) carriers after immuno prophylaxis of the infants. Methods The infants with asymptomatic HBV carriers mothers were selected by the obstetric department of Qilu Hospital of Shangdong University, Jinan Maternity and Infant Health Institute of Shangdong from Sept 2001 to Oct 2003 prospectively. Umbilical blood HBV deoxyribonucleic acid (HBV DNA) was detected at birth. All infants received 200 IU HBV specific immunoglobin(HBIG)within 12 hours and on 14 days after birth. The hepatitis B recombinant vaccine was given within 24 hours after birth and at 1 and 6 months of age. The way of feeding was chosen by the mothers as they liked. There were 55 infants in breast feeding group and 36 in bottle feeding group. Infants were then followed up at 7 and 12 months of age and tested for hepatitis B surface antigen(HBsAg), hepatitis B surface antibody (anti HBs), hepatitis B e antigen(HBeAg), hepatitis B e antibody(anti HBe) and hepatitis B core antibody(anti HBc) and HBV DNA. Uninfected infants with negative anti HBs were given repeated dose of vaccinations. Results At 7 and 12 months of age, the positive rates of HBV DNA were 9.09%(5/55)and 9.09%(5/55), anti HBs were 85.45%(47/55)and 90.90%(50/55)in breast feeding group respectively;while the positive rates of HBV DNA were 8.33%(3/36)and 8.33%(3/36), anti HBs were 86.11%(31/36)and 91.67%(33/36)in bottle feeding group respectively. No significant differences was shown in positive rates of HBV DNA and anti HBs between these two groups. Conclusions With appropriate immunoprophylaxis, including hepatitis B immune globulin and hepatitis B vaccine, HBV carriers can breast feed their babies.